Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) - Total Assets

Latest as of September 2025: CN¥2.89 Billion CNY ≈ $423.37 Million USD

Based on the latest financial reports, Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) holds total assets worth CN¥2.89 Billion CNY (≈ $423.37 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 300357 net assets for net asset value and shareholders' equity analysis.

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd - Total Assets Trend (2009–2024)

This chart illustrates how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data.

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2024)

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's total assets of CN¥2.89 Billion consist of 61.0% current assets and 39.0% non-current assets.

Asset Category	Amount (CNY)	% of Total Assets
Cash & Equivalents	CN¥0.00	41.3%
Accounts Receivable	CN¥257.87 Million	9.5%
Inventory	CN¥57.73 Million	2.1%
Property, Plant & Equipment	CN¥0.00	0.0%
Intangible Assets	CN¥181.53 Million	6.7%
Goodwill	CN¥0.00	0.0%

Asset Composition Trend (2009–2024)

This chart illustrates how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Zhejiang Wolwo Bio-Pharmaceutical Co Ltd worth.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's current assets represent 61.0% of total assets in 2024, a decrease from 62.2% in 2009.
Cash Position: Cash and equivalents constituted 41.3% of total assets in 2024, up from 35.8% in 2009.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, a decrease from 10.0% in 2009.
Asset Diversification: The largest asset category is accounts receivable at 9.5% of total assets.

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Competitors by Total Assets

Key competitors of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd based on total assets are shown below.

Company	Country	Total Assets
Pfizer Inc SA:PFIZ34	Brazil	R$208.73 Billion
CSPC Pharmaceutical Group Limited F:CVG	Germany	€46.00 Billion
Aurora Optoelectronics Co Ltd SHG:600666	China	CN¥1.60 Billion
Shandong Keyuan Pharmaceutical Co. Ltd. A SHE:301281	China	CN¥1.60 Billion
Dimed S.A. Distribuidora de Medicamentos SA:PNVL3	Brazil	R$3.83 Billion
Pfizer Inc NYSE:PFE	USA	$208.73 Billion
Merck & Company Inc NYSE:MRK	USA	$129.55 Billion
Firebrick Pharma Ltd AU:FRE	Australia	AU$1.83 Million

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	14.78	10.09	21.13
Quick Ratio	14.33	9.77	20.26
Cash Ratio	0.00	0.00	0.00
Working Capital	CN¥1.65 Billion	CN¥1.49 Billion	CN¥1.12 Billion

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd - Advanced Valuation Insights

This section examines the relationship between Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	5.43
Latest Market Cap to Assets Ratio	0.72
Asset Growth Rate (YoY)	5.7%
Total Assets	CN¥2.71 Billion
Market Capitalization	$1.95 Billion USD

Valuation Analysis

Below Book Valuation: The market values Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's assets below their book value (0.72x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's assets grew by 5.7% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (2009–2024)

The table below shows the annual total assets of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd from 2009 to 2024.

Year	Total Assets	Change
2024-12-31	CN¥2.71 Billion ≈ $396.43 Million	+5.74%
2023-12-31	CN¥2.56 Billion ≈ $374.93 Million	+16.57%
2022-12-31	CN¥2.20 Billion ≈ $321.62 Million	+13.76%
2021-12-31	CN¥1.93 Billion ≈ $282.71 Million	+20.39%
2020-12-31	CN¥1.60 Billion ≈ $234.83 Million	+12.36%
2019-12-31	CN¥1.43 Billion ≈ $208.99 Million	+35.01%
2018-12-31	CN¥1.06 Billion ≈ $154.80 Million	+24.71%
2017-12-31	CN¥848.31 Million ≈ $124.13 Million	+21.73%
2016-12-31	CN¥696.89 Million ≈ $101.98 Million	+13.97%
2015-12-31	CN¥611.49 Million ≈ $89.48 Million	+15.09%
2014-12-31	CN¥531.31 Million ≈ $77.75 Million	+101.29%
2013-12-31	CN¥263.95 Million ≈ $38.62 Million	+38.11%
2012-12-31	CN¥191.11 Million ≈ $27.97 Million	+29.84%
2011-12-31	CN¥147.19 Million ≈ $21.54 Million	+33.17%
2010-12-31	CN¥110.52 Million ≈ $16.17 Million	-8.95%
2009-12-31	CN¥121.38 Million ≈ $17.76 Million	--

About Zhejiang Wolwo Bio-Pharmaceutical Co Ltd

SHE:300357 China Drug Manufacturers - General

Market Cap

$1.95 Billion

CN¥13.30 Billion CNY

Market Cap Rank

#6380 Global

#1424 in China

Share Price

CN¥25.40

Change (1 day)

-1.82%

52-Week Range

CN¥19.38 - CN¥35.30

All Time High

CN¥5101.55